The role of Tocilizumab in treatment of a patient with COVID-19: a case report

khadijeh ezoji; Parviz Amri; Kayvan Latifi; Shahram  Seyfi

doi:10.22037/jcma.v5i2.30262

Journal of Cellular & Molecular Anesthesia

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement New Publisher Announcement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/jcma.v5i2.30262

The role of Tocilizumab in treatment of a patient with COVID-19: a case report

Author(s):

khadijeh ezoji

^1,*,

Parviz Amri

²,

Kayvan Latifi³,

Shahram Seyfi ⁴

1Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

2Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran . pamrimaleh@yahoo.com

3Specialty student of Critical Care Medicine ,Department of Anesthesiology, School of Medicine ,Babol University of Medical Sciences, Babol, Iran

4Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran

Journal of Cellular & Molecular Anesthesia:Vol. 5, issue 2; e149622

Published online:May 13, 2020

Article type:Case Report

How to Cite:khadijeh ezojiParviz AmriKayvan LatifiShahram Seyfi The role of Tocilizumab in treatment of a patient with COVID-19: a case report.J Cell Mol Anesth.5(2):e149622.https://doi.org/10.22037/jcma.v5i2.30262.

Abstract

SARS-CoV-2 (COVID-19) is an infectious disease caused by a new discovered Coronavirus. Most people infected with the COVID-19 virus recover without special treatment and experience mild to moderate respiratory disease. In the elderly and people with underlying diseases such as cardiovascular disease, diabetes, chronic respiratory disease and cancer, there is a higher risk of developing the severe form of the disease. So far, no specific drug has been found to prevent or treat COVID-19. A 52-years old diabetic man with COVID-19 was admitted to Ayatollah Rouhani Hospital Babol, Iran. After 12 days of hospitalization and treatment, with respiratory distress and oxygen saturation level to 60%, he was transferred to the intensive care unit. After receiving a 400 mg dose of actemra or tocilizumab, the patient became severely dehydrated and the oxygen saturation level reached over 90% within a few hours, and 8 days after receiving tocilizumzb (TCZ; Actemra), the patient was suffering from complications of pneumonia. So far, there have been reports of improvement in patients with Coronavirus (COVID-19) with severe actemra or tocilizumab. Typically the COVID-19 virus appears to be able to be cause the over-immune reaction and typically the cytokine storm, which often includes IL-6, therefor may be IL-6 antagonist improves patients?s condition.

Keywords

COVID-19

Actemra

Tocilizumab

References

1.
References are in the PDF file of the article.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

khadijeh ezoji:[PubMed][Scholar]
Parviz Amri:[PubMed][Scholar]
Kayvan Latifi:[PubMed][Scholar]
Shahram Seyfi :[PubMed][Scholar]